

REGULATORY RELIANCE – A REALITY

SINGAPORE EXPERIENCE

09 November 2023


Dr Rama Sethuraman
Director – Medical Devices,
Medical Devices Cluster
Health Sciences Authority, Singapore



REGULATORY RELIANCE

Regulatory Reliance

The act whereby the regulatory authority in one jurisdiction may take into account and give significant weight to (i.e., totally or partially rely on work products by) another regulatory authority or trusted institution in reaching its own decision.



Source: WHO - Good Reliance Practices in the Regulation of Medical Products: High Level Principles and Considerations



REGULATORY RELIANCE

- Promotes regulatory efficiency by leveraging the work done by other trusted agency/institution
- Enhances accessibility to safe, effective and good quality medical devices
- Allows the relying regulatory authority to retain its jurisdictional independence
 - Relies on the assessments or decisions from others
 - Retains sovereignty of decision making
 - Remains responsible and accountable for regulatory decisions taken
- Establishing an effective reliance approach requires:
 - Relying agency: Build confidence in the evaluations and assessments conducted by the other trusted agency
 - Other trusted agency: Be transparent on the evaluation and assessment criteria and practices including the decision-making processes
- Sustaining the reliance approach requires on-going engagement and collaboration between the agencies to build trust and confidence



1. ADOPTING REGULATORY RELIANCE

- HSA adopts a reliance approach to leverage approvals granted by 5 reference regulatory agencies (from Australia, Canada, European Union, Japan and the US ¹.). This speeds up our regulatory evaluations and decisions for MDs
- Prior approval from HSA's reference agencies (RAs), with identical labelled intended use.



- Safe marketing history in the respective RAs.
- → Devices may go through an evaluation route with Shorter timeline + Lower cost + Less dossier requirements.



CONFIDENCE BASED PATHWAYS - Benefits

Regulators

- Avoid duplication of regulatory oversight Not re-invent the wheel
- Effective resource management Prudent use of limited resource pool

Manufacturers

- Least burdensome regulatory process
- Cost and resource savings
- Faster market access

Patients

- Timely access to essential MDs for clinical needs
- Faster access to safe and effective technologies



2. SUPPORTING REGULATORY RELIANCE

Australia's TGA listing HSA as a Comparable Overseas Regulator for Medical Devices

- Australia's Therapeutic Goods Administration (TGA) has listed HSA as a Comparable Overseas Regulator (COR) for Medical Devices (MDs)
 - TGA is the first of the 5 reference regulatory agencies to recognise HSA as a comparable regulator
 - TGA will leverage HSA's evaluations and approvals to fast track their regulatory decision-making
 - Other CORs listed by TGA include other reputable regulators from Canada, the EU, Japan and the US



3. FACILITATING REGULATORY RELIANCE

- Singapore HSA and Thailand FDA initiated conversations on a possible regulatory reliance approach for medical devices
- Establishing an effective reliance approach requires:
 - Relying agency: Build confidence in the evaluations and assessments conducted by the other trusted agency
 - Other trusted agency: Be transparent on the evaluation and assessment criteria and practices including the decision making processes
- Sustaining the reliance approach requires on-going engagement and collaboration between the agencies to build trust and confidence



SINGAPORE HSA – THAILAND FDA REGULATORY RELIANCE

- Singapore HSA and Thailand FDA, launched the regulatory reliance pilot project in September 2020
- Confidence building measures Prior to the launch of the pilot in 2020,
 - A team from Thai FDA spent two weeks in Singapore HSA to understand HSA's medical device evaluation and assessment procedures in depth
 - Singapore HSA shared our evaluation criteria, processes and decisionmaking procedure with Thai FDA
- Prior to the launch of the pilot, a confidentiality agreement was signed between Singapore HSA and Thai FDA to allow the two agencies to freely share submission-related information with each other
- The pilot was also an opportunity to establish a practical approach to incorporate reliance into the Thai FDA's medical device evaluation process



SINGAPORE HSA – THAILAND FDA REGULATORY RELIANCE Implementing the approach



- Singapore HSA, officially announced as a reference agency for Thailand FDA (Oct 2021)
 - Expedited medical device registration program in Thailand with a shorter duration of registration
 - To be eligible, the following criteria to be met:
 - MDs must have already been registered in Singapore and requires consent from Singapore Registrant of the MD in a prescribed format

Key benefits of the Reliance approach as shared by Industry Stakeholders:

- Increase in regulatory efficiency by reducing redundancies
- Reduction in the overall registration cost for their MD in Thailand
- Significant decrease in the average review time for MDs qualifying for the reliance approach in Thailand



SINGAPORE HSA - THAILAND FDA REGULATORY RELIANCE The actual process

- Thai business operators with MD establishment license sign a letter to request participation in the Regulatory Reliance Program
- The manufacturer or importer submits an application for a medical device license through the Thai electronic submission
- After receiving an application number in the e-submission system, the Singapore registrant signs Consent Form authorizing Singapore HSA to release their evaluation report for the MD to Thai FDA and submits it via the Thai esubmission system
- Singapore HSA will share the evaluation report with Thai FDA for only those MDs for which the Singapore Registrant has signed a consent and authorised the sharing the evaluation report

Consent Form Template for the Singapore HSA-Thai FDA Reliance:

		Thailand FC	OA & Singapore HSA Reliar	ce Model Consent Form	
Medical D Health Pro	Devices Bran Devices Clus Oducts Reg iences Auth	ster ulation Group			
[Date]					
Dear Sir/N	Vladam,				
		hailand FDA and Sin	ngapore HSA Reliance Mod	el evaluation as stated bel	ow.
Device	Name	Device Registration number	Job reference number of main submission	Job reference number of(s) all change notifications filed to	Device Product Identifier
1		1		date	
		ssion Information:		date	
Full Comp Full Name Thailand I Submissio	pany Name: of Compai FDA submis on date (DD oy also decl: The eva For app approve (a) for t	in Contact Person: ssion reference nun /MM/YYYY): are that by particip aluation report will proved medical dev al, technical changes,	nber: ating in this regulatory reli be shared only after a pro- ices where change notifica	ance program, I understan duct is approved by Singap tions had been submitted	ore HSA. since initial premark
Full Comp Full Name Thailand I Submissio We hereb	oany Name: e of Compai FDA submis on date (DD yy also decl: The eva For app approve (a) for t main pi (b) for i	in Contact Person: ssion reference nun //MM/YYYY): are that by particip aluation report will proved medical dev al, technical changes, remarket evaluation notification and ad	nber: ating in this regulatory reli be shared only after a pro- ices where change notifica	ance program, I understan duct is approved by Singap tions had been submitted sluation report will be app- latest information on the S	ore HSA. since initial premark
Full Comp Full Name Thailand I Submissio We hereb	oany Name: e of Compair FDA submission date (DD ey also decla The eva For app approxi (a) for t main pi (b) for i Registe	in Contact Person: ssion reference nun //MM/YYYY): are that by particip aluation report will proved medical dev al, technical changes, remarket evaluation notification and ad	ating in this regulatory reli be shared only after a pro- ices where change notifica the change notification eva n report, and	ance program, I understan duct is approved by Singap tions had been submitted sluation report will be app- latest information on the S	ore HSA. since initial premark



SINGAPORE HSA – THAILAND FDA REGULATORY RELIANCE Learnings so far

- Resources required for the Reference Agency to share evaluation reports for a submission to the Relying Agency hence importance of planning of requests for evaluation reports
 - Post-registration in the reference agency, the MD would likely have gone through changes including significant ones that could have since modified the MD's performance or safety profile
 - Need to share the evaluation outcome, if any, for these post-registration updates with the relying agency
- Where there is new information regarding the quality, safety or efficacy of the MD, reference agency to share these, as applicable
- Regulatory reliance an important tool to manage strains on regulatory resources and improve patient access to medical devices



Thank You!